A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Overpaying for GLP-1 medications is extremely common, with a new data analysis of 102,166 drugs showing that 92% of those prescriptions could have been filled at a lower price. The DoseSpot analysis ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Many of the GLP-1 patients in their study also never reached the maximum dose. Chhabra also suspects that many people in the real world aren’t getting the supportive care and follow-up they ...

Now used for type 2 diabetes, new study shows GLP-1 drugs helped people with type 1 keep blood glucose levels in a healthy range while also losing weight.

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products In addition to persistence and adherence insights, the Year-3 study found 38% of individuals switched GLP ...

GLP-1 Prescriptions Increased 364 Percent for All Adults, and 588 Percent for Younger Adults Bariatric Surgeries Declined 42 Percent NEW YORK, May 27, 2025 /PRNewswire/ -- Over two percent of ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

About 12% of Americans say they have ever taken a GLP-1 drug, ... Head-to-head study shows bariatric surgery superior to GLP-1 drugs for weight loss (2025, June 17) ...

GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds Written by David Mills on June 20, 2025 — Fact checked by Jill Seladi-Schulman, Ph.D.

EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three ...